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ABSTRACT
OBJECTIVE
To show that limiting dual antiplatelet therapy (DAPT) 
to six months in patients with event-free ST-elevation 
myocardial infarction (STEMI) results in a non-inferior 
clinical outcome versus DAPT for 12 months.
DESIGN
Prospective, randomised, multicentre, non-inferiority 
trial.
SETTING
Patients with STEMI treated with primary percutaneous 
coronary intervention (PCI) and second generation 
zotarolimus-eluting stent.
PARTICIPANTS
Patients with STEMI aged 18 to 85 that underwent 
a primary PCI with the implantation of second 
generation drug-eluting stents were enrolled in the 
trial. Patients that were event-free at six months after 
primary PCI were randomised at this time point.
INTERVENTIONS
Patients that were taking DAPT and were event-
free at six months were randomised 1:1 to single 
antiplatelet therapy (SAPT) (ie, aspirin only) or to DAPT 
for an additional six months. All patients that were 
randomised were then followed for another 18 months 
(ie, 24 months after the primary PCI).
MAIN OUTCOME MEASURES
The primary endpoint was a composite of all 
cause mortality, any myocardial infarction, any 
revascularisation, stroke, and thrombolysis in 
myocardial infarction major bleeding at 18 months 
after randomisation.
RESULTS
A total of 1100 patients were enrolled in the trial 
between 19 December 2011 and 30 June 2015. 870 
were randomised: 432 to SAPT versus 438 to DAPT. 
The primary endpoint occurred in 4.8% of patients 
receiving SAPT versus 6.6% of patients receiving DAPT 
(hazard ratio 0.73, 95% confidence interval 0.41 to 
1.27, P=0.26). Non-inferiority was met (P=0.004 for 
non-inferiority), as the upper 95% confidence interval 
of 1.27 was smaller than the prespecified non-
inferiority margin of 1.66.
CONCLUSIONS
DAPT to six months was non-inferior to DAPT for 
12 months in patients with event-free STEMI at six 
months after primary PCI with second generation  
drug-eluting stents.
TRIAL REGISTRATION
Clinicaltrials.gov NCT01459627.
Introduction
Dual antiplatelet therapy (DAPT) after percutaneous 
coronary intervention (PCI) has been used primarily to 
avoid abrupt thrombotic closure of the vessel after stent 
implantation.1 The recommended duration of DAPT 
has been changed in the last decades, particularly after 
introduction of the first generation drug-eluting stents.2 
The observed high rates of stent thrombosis with these 
devices motivated the interventional community to 
extend DAPT to 12 months,3 although there was a 
lack of evidence for this approach. The introduction of 
second generation drug-eluting stents has drastically 
reduced the risk of stent thrombosis compared with first 
generation and bare metal stents.4-6 Different trials and 
meta-analyses have shown that shorter DAPT regimens 
after PCI with second generation drug-eluting stents are 
equally safe; however, the optimal duration of DAPT 
remains a matter of debate.5  7-9 Current international 
guidelines recommend at least six months of DAPT 
after PCI for stable ischaemic coronary disease and 
12 months in the setting of acute myocardial 
infarction.10  11 For acute coronary syndromes this 
recommendation is derived from two randomised 
trials.12 13 However, the observed benefit was noted only 
in the first months and may have been biased by the 
positive influence of upstream preloading with DAPT.
WHAT IS ALREADY KNOWN ON THIS TOPIC
The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous 
coronary intervention (PCI) with second generation drug-eluting stents is unclear
No other trial has evaluated the safety of DAPT for less than 12 months in 
patients with ST-elevation myocardial infarction (STEMI), treated with second 
generation drug-eluting stents
WHAT THIS STUDY ADDS
A dedicated randomised clinical trial to compare six versus 12 months of DAPT 
after primary PCI for patients with STEMI
Limiting DAPT duration to six months in patients with STEMI that are event-free 
results in a non-inferior clinical outcome, as assessed by a patient-oriented 
composite clinical endpoint versus 12 months of DAPT
If clinically mandated, a shorter DAPT is safe for patients with STEMI
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DAPT reduces the risk of thromboembolic events in 
general, but it is also associated with a higher risk of 
major bleeding that can sometimes be fatal.14 The risk 
of bleeding is unique to each patient and is not always 
known before PCI, particularly before primary PCI 
in the setting of a ST-elevation myocardial infarction 
(STEMI). So far, no trial has shown that extending 
DAPT from six to 12 months after primary PCI for 
STEMI is associated with a meaningful improvement 
of stent thrombosis and other safety outcomes such as 
myocardial infarction, stroke, or death. As the safety 
and efficacy profiles of second generation drug-eluting 
stents are superior to those of first generation drug-
eluting stents and bare metal stents, and considering 
the unknown risk of bleeding before primary PCI, 
it may be appealing to consider a shorter DAPT for 
patients with STEMI treated with second generation 
drug-eluting stents.
Therefore, we performed a prospective, randomised 
trial of six versus 12 months of DAPT after second 
generation drug-eluting stent implantation in patients 
presenting with STEMI (DAPT-STEMI trial) to evaluate 
whether six months of DAPT is non-inferior to 12 
months of DAPT, in patients that are event-free at six 
months follow-up after primary PCI.
Methods
Study design
The DAPT-STEMI trial is a prospective, randomised, 
multicentred, open label, non-inferiority trial designed to 
compare the clinical outcomes of six versus 12 months of 
duration of dual antiplatelet therapy (DAPT) in patients 
with ST-elevation myocardial infarction (STEMI) that 
underwent primary percutaneous coronary intervention 
(PCI) with second generation drug-eluting stents. The 
trial was conducted at 17 study sites in the Netherlands, 
Norway, Poland, and Switzerland. The study design has 
been reported.15 The trial was conducted in compliance 
with the International Conference on Harmonisation 
and the Declaration of Helsinki. The institutional 
review board of each participating institution approved 
the study. All the patients provided written informed 
consent.
Data were reviewed regularly throughout the trial by 
an independent data and safety monitoring committee. 
An independent academic clinical-events committee 
(Diagram BV), whose members were unaware of the 
group assignments, adjudicated all endpoints using 
standard definitions (see supplementary materials, 
endpoint definitions). An independent, blinded core 
laboratory judged revascularisation and stent thrombosis 
endpoints. DAPT-STEMI is an investigator driven trial.
Participant selection
The trial population consisted of patients with STEMI 
aged 18 to 85 who underwent a primary PCI with the 
implantation of second generation drug-eluting stents. 
Patients that fulfilled the inclusion and exclusion 
criteria (see supplementary materials, table e1) 
were enrolled after the primary PCI procedure. All 
patients were followed during the first six months. 
Patients that were event-free at six months follow-
up who fulfilled the randomisation criteria were at 
this time point randomised to either stop or continue 
DAPT for an additional six months. All patients that 
were randomised were then followed for another 18 
months (ie, 24 months after the primary PCI) (see 
supplementary materials, figure e1).
Interventions
All patients with STEMI were treated according to 
standard clinical practice. The choice of the vascular 
access route (ie, radial v femoral) was left to the 
discretion of the operator, although radial approach was 
strongly recommended to avoid bleeding complications 
at the puncture site. Thrombus aspiration and lesion 
predilatation were left to the discretion of the operator. 
The stent device used was the Resolute Integrity second 
generation zotarolimus-eluting stent (Medtronic, Santa 
Rosa, CA).
In accordance with international revascularisation 
guidelines,10  11 the DAPT consisted of aspirin 
loading dose of 150-300 mg orally or 250-500 mg 
intravenously followed by 75-100 mg orally daily. 
The P2Y12 inhibitors were prasugrel, ticagrelor, or 
clopidogrel. The initial dose for prasugrel was 60 mg 
orally followed by 10 mg orally daily. Patients aged 
75 years and over and with a body weight of less 
than 60 kg were treated with an initial dose of 60 mg 
prasugrel orally followed by 5 mg prasugrel orally 
daily. The initial dose of ticagrelor was 180 mg orally 
followed by 90 mg orally twice daily. The initial dose 
for clopidogrel was 600 mg orally followed by 75 mg 
orally daily. After six months, patients who fulfilled the 
inclusion and exclusion criteria were randomised, to 
either discontinue DAPT (ie, aspirin only) or continue 
DAPT for another six months after randomisation (ie, 
until 12 months after primary PCI) (see supplementary 
materials, figure e1). In all patients, 80-100 mg aspirin 
daily was continued indefinitely.
If required, additional (scheduled) staged 
revascularisations in non-culprit lesions were performed 
within 45 days from the primary PCI. However, even in 
these cases, the time of six months follow-up was based 
on the date of the initial (primary) PCI. All patients that 
were randomised were followed for 18 months after 
randomisation (ie, 24 months after primary PCI).
Outcome measures
The primary endpoint of this trial is a patient-
oriented composite endpoint of all cause mortality, 
any myocardial infarction, any revascularization, 
stroke, or thrombolysis in myocardial infarction major 
bleeding at 18 months follow-up after randomisation 
(ie, 24 months after primary PCI). The major secondary 
endpoint was a composite of all cause mortality, any 
myocardial infarction, stent thrombosis, stroke, and 
thrombolysis in myocardial infarction major bleeding 
at 18 months follow-up after randomisation. Additional 
clinical endpoints were the individual components 
of the primary endpoint. Trial endpoint definitions 
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are provided in the supplementary materials. For 
the purpose of the primary endpoint, myocardial 
infarction was adjudicated based on the Academic 
Research Consortium definitions.16 Stroke was defined 
as any acute neurological event with a duration of 
at least 24 hours, with focal signs and symptoms 
and without evidence supporting any alternative 
explanation, and confirmed by imaging by computed 
tomography or magnetic resonance imaging, or by 
pathological evidence. Bleeding was evaluated based 
on the thrombolysis in myocardial infarction bleeding 
classification.17
Sample size and statistical analyses
The trial was designed to test the hypothesis that 
single antiplatelet therapy (SAPT) with aspirin after 
six months in patients with STEMI that were event-
free would be non-inferior to DAPT with respect to the 
primary endpoint. We estimated the hazard ratio of the 
primary endpoint in the treatment and control groups 
using a Cox proportional-hazards model. A pre-defined 
non-inferiority margin of 1.66 was used in this trial. 
Non-inferiority of SAPT versus DAPT will be concluded 
if the estimated 95% confidence interval of the hazard 
ratio lies entirely below this margin. If the upper limit 
of the 95% confidence interval exceeds this margin 
we do not reject the null hypothesis of inferiority. The 
non-inferiority margin chosen in our trial, reflects the 
knowledge from other trials within cardiology that 
were available in the literature when this trial was 
designed.18-21
The sample size was calculated under the assump-
tion that the α value was 0.05 for a two sided test 
(0.025 for a one sided test) with a power of 85%. 
The endpoint at 18 months after randomisation was 
assumed to be 15%. Taking into account the patients 
that were ineligible for randomisation owing to clinical 
events in the first six months or other exclusion criteria, 
a total sample size of 1100 patients was required.
The primary analysis, which was performed on 
an intention to treat basis, included all patients that 
underwent randomisation, regardless of whether 
they received treatment. The results for the primary 
endpoint are presented as time to event curves 
(Kaplan-Meier). We based the P values comparing the 
clinical outcomes in the treatment groups on logrank 
tests. We calculated hazard ratios and corresponding 
95% confidence intervals using Cox proportional 
hazards models. We calculated the P value for non-
inferiority by testing the estimated hazard ratio 
against the non-inferiority hazard ratio of 1.66. We 
assumed an approximate posterior distribution for 
the treatment effect based on the estimated hazard 
ratio and its standard error. We used this to derive the 
probability that the true hazard ratio is over 1.66. All 
tests were two tailed and conducted at a significance 
level of 0.05. Data for patients that did not have an 
endpoint event were censored for the analysis of that 
endpoint at the time of the last known contact or at 
18 months (ie, 24 months after the primary PCI), 
whichever was earlier. For descriptive purposes, a 
sensitivity analysis on a per protocol basis for the 
primary endpoint was performed. Analysis were 
performed with IBM statistical package for social 
sciences (SPSS) version 24 and SAS version 9.4 (SAS 
Institute, Cary, NC).
Patient and public involvement
No patients were involved in setting the research 
question or the outcome measures, nor were 
they involved in developing plans for design or 
implementation of the study. The ethical committee 
had a patient representative member. No patients 
were asked to advise on interpretation or writing up of 
results. There are no plans to disseminate the results 
of the research to study participants or the relevant 
patient community.
Results
Patient characteristics
Between 19 December 2011 and 30 June 2015, a total 
of 1100 patients were enrolled in the trial. Figure 1 
shows that 230 (20.9%) of these patients were not 
randomised after six months of follow-up. Of the 230 
patients that were excluded, 138 were not eligible for 
randomisation: 55 patients had events during the first 
six months and 83 did not fulfil the other randomisation 
criteria. A total of 92 patients were eligible but were not 
randomised. Among those who were eligible but did 
Assigned to DAPT (n=437)Assigned to SAPT (n=433)
Included in 15 month follow-up (n=435)Included in 15 month follow-up (n=432)
Included in 24 month follow-up (n=432)Included in 24 month follow-up (n=429)
Patients enrolled who had STEMI (n=1100)
Randomisation at 6 months (n=870)
Treatment: 6 months of DAPT
Excluded (n=230):
  Not eligible (n=138):
    Had events (n=53):
      Died (n=9)
      Myocardial infarction (n=7)
      Stroke (n=2)
      Stent thrombosis (n=10)
      Target lesion revascularisation or target vessel revascularisation (n=19)
      Bleeding (n=6)
    Oral anticoagulation (n=39)
    Planned percutaneous coronary intervention or coronary artery bypass gra (n=31)
    Other exclusion criteria (n=15)
  Eligible but did not undergo randomisation (n=92):
    Unwilling (n=69)
    No contact in time window possible (n=23)
Withdrew consent (n=1) Excluded (n=2):
  Withdrew consent (n=1)
  Unavailable (n=1)
Unavailable (n=3) Unavailable (n=3)
Fig 1 | Study flow diagram
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not undergo randomisation, the most common reason 
was withdrawal of consent during the six months 
between enrolment and randomisation (69 patients). 
A total of 870 patients were randomised.
Complete information on the primary endpoint 
was obtained for 99% (861/870) of the randomised 
patient population. Figure 1 shows that at 15 months 
follow-up, one patient was lost and two patients 
withdrew consent. For the final 18 months follow-up 
(ie, 24 months after the primary PCI), six patients were 
unavailable, but were known to be alive. 
Table 1 shows that the two treatment groups were 
well balanced with respect to baseline characteristics. 
On average, patients were 60 years old and 76.9% of 
them were male.
In the DAPT arm of the trial, six patients received 
DAPT for fewer than 12 months; two because of 
bleeding events and four because of poor compliance. 
In the SAPT arm of the trial, 14 patients received DAPT 
for more than six months; four took SAPT with P2Y12 
inhibitor and 10 continued DAPT without evident 
reason. These crossovers were based on the patient’s or 
doctor’s preference. None of these patients had major 
cardiac adverse events.
Primary endpoint
During the 18 months after randomisation (ie, 24 
months after the primary PCI), the primary endpoint, 
a composite of all cause mortality, any myocardial 
infarction, any revascularization, stroke, or 
thrombolysis in myocardial infarction major bleeding 
occurred in 4.8% in the SAPT group versus 6.6% 
in the DAPT group (hazard ratio SAPT v DAPT 0.73, 
95% confidence interval 0.41 to 1.27; P=0.26). Non-
inferiority was met (P=0.004 for non-inferiority), as 
the upper 95% confidence interval of 1.27 is smaller 
than the prespecified non-inferiority margin of 1.66 
(see table 2 and fig 2).
The per protocol analysis of the primary endpoint 
confirmed the result of the main (intention to treat) 
analysis, (hazard ratio 0.74, 95% confidence interval 
0.42 to 1.30; P=0.005 for non-inferiority).
The hazard ratio proportionality assumption was 
examined by graphical checks (see supplementary 
materials, fig e2) and by applying supremum tests 
(see supplementary materials, fig e3) using the assess 
statement in Proc PHREG in SAS. Non-inferiority of 
SAPT versus DAPT was calculated across different 
thresholds of the hazard ratio. Table 3 shows that 
the trial could prove the non-inferiority not only for 
the chosen non-inferiority margin of 1.66 but for any 
hazard ratio margin above 1.2.
Secondary endpoints
The major secondary endpoint, a composite of safety 
and bleeding at 18 months (ie, 24 months after the 
primary PCI), occurred in 3.2% in the SAPT group 
versus 4.3% in the DAPT group (hazard ratio 0.75, 
95% confidence interval 0.37 to 1.49; P=0.40). 
Between the two treatment groups, there was no 
statistically significant difference in the incidence of 
all cause mortality (0.7% v 1.4%, hazard ratio 0.51, 
95% confidence interval 0.13 to 2.02; P=0.33); death 
from cardiac causes (0.5% v 0.9%, 0.51, 0.09 to 2.76; 
P=0.43); any myocardial infarction (1.8% v 1.8%, 
1.02, 0.38 to 2.71; P=0.97); stent thrombosis (0.7% 
v 0.9%, 0.76, 0.17 to 3.39; P=0.72); stroke (0.7% v 
0.7%, 1.02, 0.21 to 5.03; P=0.99); and thrombolysis 
in myocardial infarction major bleeding (0.2% v 0.5%, 
0.51, 0.05 to 5.57; P=0.58) (see table 2).
Discussion
Principal findings
This study is the first dedicated randomised 
clinical trial to compare six versus 12 months of 
Table 1 | Patient characteristics. Values are numbers (percentages) unless stated 
otherwise
Characteristic SAPT (n=433) DAPT (n=437)
Patient characteristic
Age (years) 59.8±10.7 60.2±10.3
Male 337 (78%) 332 (76%)
Body mass index 27.8±4.3 27.9±4.5
Medical history
Previous coronary artery bypass graft 8 (2%) 2 (0.5%)
Previous percutaneous coronary intervention 29 (7%) 18 (4%)
Previous myocardial infarction 26 (6%) 20/436 (5%)
Stroke or transient ischaemic attack 14 (3%) 8/436 (2%)
Peripheral arterial disease 16 (4%) 9/436 (2%)
Congestive heart failure 16 (4%) 19/436 (4%)
Risk factors
Diabetes mellitus 54 (13%) 61 (14%)
Hypertension 193 (45%) 195/436 (45%)
Dyslipidaemia 120 (28%) 125/436 (29%)
Current smoker 218/431 (51%) 205 (47%)
Family history of coronary artery disease 143/431 (33%) 144/436 (33%)
Drugs at start of study
P2Y12 inhibitors:
 Clopidogrel 180 (42%) 182 (42%)
 Prasugrel 128 (29%) 132 (30%)
 Ticagrelor 125 (29%) 123 (28%)
Percutaneous coronary intervention
Thrombolysis in myocardial infarction flow:
 Baseline <3 355/432 (82%) 355 (81%)
 After PCI 3 411 (95%) 421/436 (97%)
Infarct related artery:
 Left anterior descending 169 (39%)* 188 (43%)
 Right coronary artery 175 (41%) 179 (41%)
 Right circumflex artery 89 (21%) 70 (16%)
Lesion type culprit:
 B2 158/428 (37%) 158/433 (36%)
 C 108/428 (25%) 101/433 (24%)
Stent type culprit†:
 Zotarolimus-eluting stent 400/432 (93%) 407/436 (93%)
 Other 32/432 (7%) 29/436 (7%)
Index procedure:
 Treated lesions 1.09±0.3 1.10±0.3
 Treated vessels 1.08±0.3 1.07±0.3
 Stents 1.42±0.8 1.48±0.8
 Total stent length (mm) 28.5±16 29.8±16
Minimum stent diameter (mm)‡:
 <3 189/613 (31%) 178/645 (28%)
 ≥3 424/613 (69%) 467/645 (73%)
Non-culprit lesion intervention 54 (12.5%) 62 (14%)
*One patient had left main as infarct related artery.
†One patient received plain old balloon angioplasty without additional stenting.
‡Total is number of stents used during index procedure.
 o
n
 15 O
ctober 2018 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.k3793 on 2 October 2018. Downloaded from 
RESEARCH
the bmj | BMJ 2018;363:k3793 | doi: 10.1136/bmj.k3793 5
dual antiplatelet therapy (DAPT) after primary 
percutaneous coronary intervention (PCI) for ST-
elevation myocardial infarction (STEMI). The trial 
showed that limiting DAPT to six months in patients 
that were event-free resulted in a non-inferior 
clinical outcome, as assessed by the patient-oriented 
composite clinical endpoint of safety, efficacy, 
and bleeding, versus the currently recommended 
regimen of 12 months DAPT. Furthermore, no 
noticeable difference was observed with regard to the 
major secondary composite endpoint of safety and 
bleeding. In addition, neither statistically significant 
nor meaningful numerical differences were observed 
for the components of the composite endpoints: 
all cause mortality, any myocardial infarction, 
any revascularisation, stent thrombosis, stroke, 
or thrombolysis in myocardial infarction major 
bleeding. The primary endpoint, as well as all its 
individual components showed low event occurrence 
in both treatment arms, suggesting that patients 
that were event-free at six months remain at a low 
risk for further events, irrespective of whether DAPT 
is continued or not. Our findings are in line with 
those of other randomised studies which compared 
six versus 12 months of DAPT.22-24 Our findings also 
support the low number of events seen in patients 
with STEMI after PCI with second generation 
drug-eluting stents. Another interesting finding 
which can be observed from the Kaplan-Meier curves 
is that stopping DAPT (both in the six and 12 months 
arms) was not associated with a rebound effect on 
primary endpoint events. This may suggest that DAPT 
may have no further protective effect beyond these 
points in time, however, further data are needed to 
explore specifically the potential rebound effect of 
DAPT discontinuation at different time points.
Table 2 | Clinical outcomes at 18 months after randomisation. Values are numbers (percentages) unless stated 
otherwise 
Outcome SAPT (n=433) DAPT (n=437)
Hazard ratio SAPT v DAPT 
(95% CI) P value
Primary endpoint
Composite* 21 (4.8%) 29 (6.6%) 0.73 (0.41 to 1.27) 0.26 
0.004 for  
non-inferiority
Secondary endpoints
Composite† 14 (3.2%) 19 (4.3%) 0.75 (0.37 to 1.49) 0.40
Death: 3 (0.7%) 6 (1.4%) 0.51 (0.13 to 2.02) 0.33
  Cardiac 2 (0.5%) 4 (0.9%) 0.51 (0.09 to 2.76) 0.43
Myocardial infarction 8 (1.8%) 8 (1.8%) 1.02 (0.38 to 2.71) 0.97
Revascularisation: 13 (3.0%) 17 (3.9%) 0.87 (0.42 to 1.83) 0.72
  Urgent 8 (1.8%) 13 (3.0%) 0.83 (0.34 to 1.99) 0.67
  Target lesion 4 (0.9%) 4 (0.9%) 1.02 (0.25 to 4.06) 0.98
  Target vessel, non-target lesion 2 (0.5%) 5 (1.1%) 0.40 (0.08 to 2.08) 0.28
  Non-target vessel 6 (1.4%) 10 (2.3%) 0.76 (0.26 to 2.18) 0.61
Stent thrombosis 3 (0.7%) 4 (0.9%) 0.76 (0.17 to 3.39) 0.72
Stroke 3 (0.7%) 3 (0.7%) 1.02 (0.21to 5.03) 0.99
Bleeding: 3 (0.7%) 5 (1.1%) 0.61 (0.15 to 2.53) 0.49
  Thrombolysis in myocardial infarction major 1 (0.2%) 2 (0.5%) 0.51 (0.05 to 5.57) 0.58
  BARC type 3 2 (0.5%) 4 (0.9%) 0.50 (0.09 to 2.75) 0.43
Target lesion failure‡ 5 (1.2%) 8 (1.8%) 0.63 (0.21 to 1.93) 0.42
Hospital stay: 33 (7.6%) 38 (8.7%) 0.92 (0.58 to 1.48) 0.74
  Cardiac 26 (6.0%) 33 (7.6%) 0.84 (0.50 to 1.42) 0.52
  Chest pain 11 (2.5%) 13 (3.0%) 0.93 (0.41 to 2.10) 0.85
*All cause mortality, any myocardial infarction, any revascularization, stroke, and thrombolysis in myocardial infarction major bleeding (net adverse clinical 
events).
†All cause mortality, any myocardial infarction, stent thrombosis, stroke, and thrombolysis in myocardial infarction major bleeding.
‡Cardiac death, target lesion revascularization, or target lesion myocardial infarction. 
BARC=Bleeding Academic Research Consortium
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Fig 2 | Cumulative incidence of the primary composite 
endpoint. The number at risk was defined as the number 
of patients who had not had the event of interest and who 
were available for subsequent follow-up
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The low event rates after primary PCI with the 
Resolute Integrity second generation zotarolimus-
eluting stent might be attributed to the improved 
design of this device, as compared with first generation 
drug-eluting stents. Indeed, thinner stent struts favour 
a better and homogeneous endothelial strut coverage 
as compared with the thicker stainless steel struts of 
the first generation drug-eluting stents,25 and drug-
eluting stents with thin struts have shown a low risk 
of adverse cardiovascular events in patients with a 
variety of clinical syndromes.26 The Resolute Integrity 
second generation zotarolimus-eluting stent uses a 
biocompatible durable polymer that enables longer 
drug elution and has shown to affect the amount of 
neointima compared with the previous zotarolimus-
eluting platform.27 Moreover the almost complete 
neointimal coverage within three months after the 
implantation of Resolute Integrity second generation 
zotarolimus-eluting stent, as observed by optimal 
coherence tomographic studies, supports a shorter 
DAPT period.28 29
On the other hand, it is well known that patients 
with STEMI may have multiple complex coronary 
plaques, associated with a generally increased risk 
of adverse cardiovascular events,30 as well as other 
vulnerable plaques with traits of instability elsewhere 
in their coronary tree.31 Nevertheless, remaining 
complex “non-culprit” lesions are now generally 
treated after or even during the primary PCI. Regarding 
the remaining non-significant lesions with traits of 
“vulnerability,” the current understanding is that 
many of these characteristics may be short lived, 
as in most cases these plaques progress through a 
process of asymptomatic plaque rupture and healing 
to more stable atherosclerotic lesions while other 
plaques remain unchanged.32 Therefore, based on 
this understanding of atherosclerosis progression, it 
is much more likely that these plaques may remain 
clinically silent or manifest as stable rather than an 
acute coronary syndrome. As such, while DAPT as 
secondary prevention may reduce cardiovascular 
events originating from atherosclerosis progression 
elsewhere in the coronary tree,33  34 these events are 
rare and the benefits of the reduction of ischaemic 
events may not outweigh the increase in the risk of 
bleeding, related to prolonged DAPT, as recently shown 
in the Pegasus and DAPT trials.33 35 Major bleeding is 
an adverse event that is strongly related to mortality.36 
Recent studies have even shown that bleeding is a 
stronger predictor of non-cardiovascular mortality 
than thromboembolic and ischaemic events.36  37 
Indeed, prolonged DAPT did not impact mortality 
in the Pegasus and OPTIDUAL trials,33  38 but it was 
associated with a higher all cause mortality in the 
DAPT trial.35 Based on this evidence and considering 
that atherosclerosis is a lifelong disease, the role of 
DAPT in secondary prevention remains questionable. 
While DAPT does not have a major impact on the 
progression of atherosclerosis which in a large extent 
is based on rupturing and healing plaques, it might 
have some impact on its clinical presentation. In other 
words: the use of DAPT may result in more patients 
presenting with stable angina pectoris rather than 
acute coronary syndromes.39 As this could influence 
the need for ischemia-driven revascularization during 
the treatment period, we incorporated the endpoint 
“any revascularisation” into the primary clinical 
endpoint of our trial.
Finally, given the potential trade-off between 
ischaemic versus bleeding risks for any given duration 
of DAPT, the use of scores might prove useful to tailor 
DAPT.11 However, while the DAPT score estimates 
ischaemic and bleeding risks for prolonged DAPT 
and the PRECISE DAPT and PARIS risk scores predict 
bleeding during DAPT supporting clinical decision 
making for treatment duration, none of these risk 
prediction models have been prospectively tested in 
the setting of a randomised controlled trial, and even 
less in patients with STEMI.40-43 Therefore, the value of 
the risk scores in improving patient outcomes remains 
unknown.
Limitations of the study
This study has limitations. The primary endpoint is 
a combined endpoint of major adverse cardiac and 
cerebrovascular events and bleeding. While this 
endpoint might not give clear insights for each of these 
components, considering the bivalent impact of DAPT 
so much in ischaemic as well as bleeding outcomes 
we believe this endpoint gives better insights to the 
overall patient outcome. Moreover, individual clinical 
endpoints were not in opposite directions when 
comparing DAPT versus SAPT. Excluding the patients 
with events in the 6 months does indeed introduce a 
bias of patients at low risk, however, rather than being 
a selection bias, it reflects more the trial design.
In this trial, the rate of patient enrolment was not 
high. This may reflect the absence of previous data 
in this setting and the difficulty of obtaining patient 
consent to participate in the trial, this was also reflected 
by the high number of withdrawals at six months.
The lower than estimated occurrence of events in both 
arms, may be perceived as another limitation of this 
trial, but reflects the design of this trial: only patients 
that were event-free at six months were randomised, 
which may have excluded a certain proportion 
Table | 3 Non-inferiority of SAPT versus DAPT calculated 
across different thresholds of the hazard ratio
Hazard ratio threshold Wald χ2 DF Pr >χ2
1.1 2.1037 1 0.1469
1.2 3.0768 1 0.0794
1.3 4.1349 1 0.0420
1.4 5.2536 1 0.0219
1.5 6.4154 1 0.0113
1.66 8.3323 1 0.0039
Wald statistic was used to test the estimated parameter against a 
hypothetical population value. The Wald test was computed as the 
squared difference of the parameter estimate (B) against the hypothetical 
value divided by the standard error estimate. In a test for the global null 
hypothesis the parameter estimate was tested against a value of 0 (HR=1). 
The other tests tested whether the estimated parameter differs from 0.095 
for a hazard ratio of 1.1, from 0.182 for a hazard ratio of 1.2 etc. The Wald 
test was performed using Proc PHREG in SAS 9.4.
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of patients at higher risk from randomisation. 
Furthermore, the observed event occurrence is in line 
with previous trials performed with modern drug-
eluting stents.23  44 To avoid the biases that the low 
event occurrence could introduce to a non-inferiority 
design based on a fixed percentage of the expected 
event, we chose a non-inferiority design based on 
hazard ratios. In this model, lower than expected event 
occurrence would enlarge the confidence intervals 
and therefore challenge the non-inferiority, however, 
this was not the case in our trial as the hazard ratio 
was 0.73 and the upper confidence interval was 1.27, 
much lower than the prespecified margin of 1.66. 
Considering that our endpoint did combine ischaemic 
and bleeding events, we were expecting a benefit for 
SAPT,23  33  35  44 and therefore we could have chosen a 
more conservative non-inferiority margin than 1.66, 
however, taking into account a possible chance finding 
(a benefit in favour of DAPT) we chose a wider margin. 
It has to be noted that the large non-inferiority margin 
did not influence the observed non-inferiority as a post 
hoc analysis showed that the trial would have proved 
non-inferior even for a much more conservative non-
inferiority margin of 1.3 (see table 3).
Another limitation is that fewer patients than 
predicted were randomised at six months follow-up. 
The design of the trial in which only patients that 
were event-free at six months could be randomised 
contributed to this issue; other reasons were the 
higher than expected number of withdrawals and 
the treatment of non-culprit coronary lesions outside 
the prespecified accepted time window for staged 
PCI procedures, which we could not predict when 
designing the trial. Indeed, the last reason also explains 
in part why the number of non-culprit coronarylesion 
treatments in this trial appears low. However, a post 
hoc analysis showed that the number of actual versus 
planned patients that were randomised had only a 
minimal influence in the trial power reducing it by only 
3%.
The time from the onset of pain until revascularisation 
as well as door to balloon time were not recorded in 
this trial, however, considering that the randomisation 
occurred only at six months in patients that were event-
free, such information would not importantly impact 
the trial outcomes.
Per protocol, the choice of the P2Y12 inhibitor 
prescribed was at the operators’ discretion reflecting 
the guidelines when this trial was designed. As can 
be observed in the baseline table, the different P2Y12 
inhibitors were similarly distributed between treatment 
groups. Different P2Y12 inhibitors have different 
outcomes in safety endpoints or bleeding;45 however, 
potential differences in outcomes between patients 
treated with different P2Y12 inhibitors can only be 
appreciated in studies with much larger population 
sizes than our present trial. Furthermore, because we 
used a composite endpoint, any possible advantage 
of prasugrel or ticagrelor in ischaemic outcomes is 
counterbalanced from the bleeding outcomes. We do 
not expect that clopidogrel introduced any bias in our 
results, and if so it would rather underestimate the 
benefit of SAPT. Moreover, according to guidelines when 
neither prasugrel or ticagrelor are available, or if they 
are contraindicated, clopidogrel should be prescribed. 
Thus the presence of clopidogrel in our trial may still 
be of importance for those patients that are treated with 
clopidogrel, especially in countries which, for economic 
reasons, cannot afford the cost of new P2Y12 inhibitors.
The Resolute Integrity second generation 
zotarolimus-eluting stent was used in 93% of the 
patients and thus further studies with other second 
generation drug-eluting stents will be required 
to establish the extension of this finding. Finally, 
although cardiogenic shock was not an exclusion 
criteria for enrolment, patients with overt cardiogenic 
shock were not enrolled because they were not able to 
provide informed consent and therefore, the results of 
this trial cannot apply to these patients as well as for 
patients with lesions requiring left main stenting who 
were excluded from the trial.
Conclusions
In patients that are event-free six months after primary 
PCI with second generation drug-eluting stents, six 
months of DAPT was associated with outcomes not 
inferior to those observed after 12 months of DAPT. 
While larger trials have shown that longer duration of 
DAPT regimens might be associated with favourable 
ischaemic outcomes, this trial for the first time shows 
that a shorter DAPT duration is also feasible and safely 
applicable if clinically required even in patients with 
STEMI, setting the stage for further dedicated research 
on DAPT duration in this category of patients that are 
at high risk.
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